Four-year results from PATRO Children, a multi-centre, non-interventional study of the long-term safety and efficacy of Omnitrope[®] in children requiring growth hormone treatment

Pfäffle R,¹ Kanumakala S,² Höybye C,³ Kriström B,⁴ Battelino T,⁵ Colle M,⁶ Zabransky M⁷

¹Department of Paediatric Endocrinology, University of Leipzig Medical School, Leipzig, Germany; ²Department of Paediatrics, Royal Alexandra Children's Hospital, Brighton, UK; ³Department of Endocrinology, Metabolism and Diabetology, Karolinska University Hospital, Stockholm, Sweden; ⁴Department of Clinical Science/Paediatrics, Umeå University, Sweden; ⁵Department of Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, Llubljana, Slovenia; ⁶25 rue Boudet, Bordeaux, France; ⁷Sandoz GmbH, Holzkirchen, Germany.

Introduction

- Recombinant human growth hormone (rhGH, somatropin) has been used for many years to treat growth disorders in children, but some concerns remain about its long-term safety.¹
- Omnitrope[®] is a rhGH biosimilar approved by the European Medicines Agency in 2006, with approval granted on the basis of comparable quality, safety and efficacy to the reference product (Genotropin[®], Pfizer).²
- Omnitrope[®] has been approved in the following indications:²
- growth hormone deficiency (GHD)
- Turner syndrome (TS)
- chronic renal insufficiency (CRI)
- born small for gestational age (SGA)
- Prader-Willi syndrome (PWS)
- idiopathic short stature (ISS; USA, Canada and Brazil only).
- The PAtients TReated with Omnitrope[®] (PATRO) Children study is an ongoing, Height velocity <1 of

	Total (n=1640) (%)
Patient reached final height/bone age maturation	29.8
Miscellaneous reasons	16.8
Lost to follow-up	12.1
Patient does not wish to continue the injections	10.7
Switch to other growth hormone product	6.9
Patient satisfied with current height	5.2
Reached near final height	5.2
Non-responder	4.8
Adverse event	3.5
Patient non-compliant	3.1
Referral to adult endocrinologist	0.7
Unknown	0.6

Table 4. Drug-related SAEs resulting in treatment disruption Gender, Action taken SAE Indication Outcome (preferred term) with treatment Age Male, 9 GHD Resolved completely Headache Interrupted Benign intracranial GHD Female, 6 Resolved completely Interrupted hypertension Male, 8 GHD Gait disturbance Resolved completely Interrupted Neoplasm Male, 19 GHD Resolved completely Interrupted progression Permanently Intracranial pressure Male, 4 SGA Resolved completely discontinued increased Permanently Male, 14 SGA Resolved completely Heart injury discontinued Type I diabete D nthu

P1-634

long-term, post-marketing surveillance programme for Omnitrope[®].³

Objectives

- The main objective of PATRO Children is to assess the long-term safety of Omnitrope[®], particularly in terms of the diabetogenic potential of rhGH therapy, the risk of malignancies and potential risks of rhGH in children with PWS.
- The long-term efficacy of Omnitrope[®] is analysed as a secondary objective through changes in height parameters.
- Here, we present an interim analysis of safety and efficacy data up to 4 years after the start of treatment with Omnitrope[®].

Methods

- International, observational, longitudinal, non-interventional study, currently being conducted across 14 different countries (Study EP00-501).³
- In brief, infants, children and adolescents who require rhGH treatment and receive at least one dose of Omnitrope® were enrolled. Patients previously treated with another somatropin product could also be included.
- Omnitrope[®] is administered as part of usual clinical practice in the centres involved and doses are given according to country-specific prescribing information. All patient data are captured in an electronic case report form.

Safety assessments

- All adverse events (AEs) are recorded at each visit for the complete duration of rhGH treatment.
- Fasting plasma glucose, 2-hour oral glucose tolerance tests, insulin levels, glycosylated haemoglobin and anti-GH antibodies are requested to be documented according to routine clinical practice.

Efficacy assessments

 Auxological data may be registered at each visit. Height velocity (HV, cm/year), height standard deviation score (HSDS) and HVSDS are derived from height measurements and country-specific reference tables.

Height velocity < 1 cm/year	0.4
Withdrawal of informed consent	0.2

Table 3. Summary of AEs

	Total number of subjects n=5007	n	%						
	Any AE	1924	38.4						
Relationship to	Not suspected	1836	36.7						
study drug [']	Suspected	284	5.7						
	Mild	1481	29.6						
latonsit (Moderate	861	17.2						
Intensity	Severe	186	3.7						
	Missing	326	6.5						
	Not changed	1790	35.7						
	Increased	66	1.3						
Changes to	Reduced	43	0.9						
Omnitrope [®] treatment	Interrupted	126	2.5						
	Permanently discontinued	56	1.1						
	Missing	93	1.9						
SAEs	No	1832	36.6						
JALS	Yes	323	6.5						
	Headache	75	1.5						
	Arthralgia	19	0.4						
	Injection site haematoma	19	0.4						
	Injection site pain	18	0.4						
Treatment-related	Hypothyroidism	13	0.3						
AEs (>5 patients), by MedDRA	Pain in extremity	10	0.2						
by MedDRA	Scoliosis	8	0.2						
preferred term	Insulin-like growth factor increased	8	0.2						
	Drug ineffective	7	0.1						
	Myalgia	5	0.1						
	Glucose tolerance impaired	5	0.1						
	Insulin resistance	5	0.1						
MadDRA Madical Dictionary for Pagulatory Activities									

Female, 14	SGA	lype I diabetes mellitus	Permanently discontinued	Ongoing	
Male, 8	SGA	Osteochondrosis	Permanently discontinued	Ongoing	
Male, 10	lle, 10 PWS Upper airway resistance syndrome		Interrupted	Ongoing	
Male, 16	ISS	Kyphosis	Permanently discontinued	Ongoing	

Figure 1. The positive effect of Omnitrope® on mean HSDS in both naïve and pre-treated patients with GHD or born SGA.




Figure 2. Height velocity SDS (peak-centred) for pre-treated and naïve GHD and

Results

Patients and treatment

- As of July 2016, 5007 patients have been enrolled; all patients have been included in the safety set.
- The baseline characteristics are presented in Table 1. The mean age for the total population is 9.1 years and 61.8% are males (excluding TS patients).
- In total, 775 patients (15.5%) had been pre-treated with another rhGH before study entry and were transferred to Omnitrope[®].
- The mean (SD) treatment duration of Omnitrope[®] was 32.4 (22.8) months. The mean (SD) daily dose of Omnitrope[®] at baseline was 0.033 (0.01) mg/kg/day.

Safety

- 1640 patients have discontinued treatment; most commonly due to reaching final height/bone maturation (29.8%), with very few (3.5%) discontinuing due to AEs (Table 2). The reason was unknown or not documented in 0.6% of patients.
- Overall, 1924 patients (38.4%) experienced AEs, most of which were mild to moderate. rhGH treatment was interrupted in 126 patients (2.5%) and the rhGH dose was reduced in 43 patients (0.9%) (Table 3).
- Of the 323 patients (6.5%) who experienced serious AEs (SAEs), only 30 (0.6%) experienced SAEs considered to be possibly related to treatment. Of these, 10 resulted in discontinuation or interruption of Omnitrope[®] treatment (Table 4).

Table 1. Patient characteristics at baseline

Indication	Naïve/pre- treatedª	Total (n)	Male/female (n)	Mean age, years (SD)	Mean BMI SDS (SD)	Mean HSDS (SD)	Mean HV,cm/ year (SD)	Mean peak-centred HV SDS (SD)	
	Naïve	2421	1611/810	9.5 (3.8)	-0.2 (1.3)	-2.5 (0.9)	3.7 (2.0)	-2.9 (2.6)	
GHD	Pre-treated	433	290/143	11.4 (3.4)	–O.1 (1.3)	-1.5 (1.1)	5.2 (2.4)	-0.3 (3.3)	
	Naïve	1088	557/531	7.8 (3.3)	-0.8 (1.3)	-2.9 (0.8)	4.0 (2.1)	-2.7 (2.3)	
SGA	Pre-treated	192	112/80	10.1 (2.8)	-0.3 (1.3)	-1.6 (1.2)	4.9 (2.1)	-0.9 (3.0)	
тс	Naïve	178	-/178	8.9 (4.5)	0.2 (1.4)	-3.1 (1.1)	3.5 (1.8)	-2.4 (1.9)	
TS	Pre-treated	50	-/50	10.6 (3.7)	0.9 (1.0)	-1.8 (1.2)	4.2 (2.2)	-1.3 (3.1)	
	Naïve	130	66/64	3.0 (3.2)	0.2 (2.2)	-1.6 (1.5)	8.8 (4.7)	-3.1 (2.4)	
PWS	Pre-treated	24	12/12	8.6 (4.9)	1.6 (1.5)	-0.2 (1.3)	5.4 (2.9)	-1.0 (3.4)	
	Naïve	32	20/12	6.6 (4.6)	0.0 (1.8)	-2.8 (1.2)	3.6 (2.7)	-5.6 (2.4)	
CRI	Pre-treated	4	2/2	10.3 (3.0)	0.5 (2.0)	-2.4 (1.1)	6.7 ()	O.8 (—)	
	Naïve	24	16/8	9.6 (3.6)	0.0 (1.4)	-2.3 (1.1)	2.0 (2.5)	-4.6 (3.4)	
ISS	Pre-treated	23	18/5	10.6 (3.6)	-0.2 (0.8)	-1.4 (0.9)	6.6 (3.2)	1.4 (4.8)	
	Naïve	298	177/121	9.6 (3.7)	-0.4 (1.4)	-2.8 (1.2)	3.6 (2.0)	-3.0 (2.7)	
Other	Pre-treated	49	37/12	9.8 (3.7)	-0.2 (1.1)	-1.7 (1.3)	5.1 (2.7)	-1.2 (2.9)	
Unknown	Naïve	3	2/1	9.3 (6.5)	-1.5 (1.5)	-3.0 (0.5)	2.2 ()	-6.9 ()	
Total		5007	2951/2056	9.1 (3.9)	-0.3 (1.4)	-2.5 (1.1)	4.2 (2.4)	-2.2 (3.0)	
Pre-treatment information was unavailable for 58 patients (31 male, 27 female); BMI, body mass index; CRI, chronic renal insufficiency; GHD, growth hormone deficiency; HV, height velocity; HSDS, height standard deviation deviation score; SGA, born small for gestational age; TS, Turner syndrome; PC, peak-centred									

MedDRA=Medical Dictionary for Regulatory Activities

- In total, 126 samples from 67 patients were assessed for anti-hGH antibodies. Only one positive anti-hGH antibody titre occurred transiently in a treatmentnaïve patient at baseline; all subsequent results for this patient were negative. So far, 12 patients have been tested for anti-hGH antibodies following two years of Omnitrope[®] treatment; no positive anti-hGH antibody titres have been reported in these patients.
- To date, there have been no reports of any additional safety concerns.

Efficacy

- After 4 years of treatment, Omnitrope[®] resulted in improvements in growth parameters across all indications, irrespective of gender or pre-treatment status.
- Greater height gains at 4 years were observed amongst naïve patients, with a mean HV (SD) of 6.4 (1.9) and 5.8 (1.6) cm/year in naïve patients with GHD and SGA, respectively.
- The effect of Omnitrope[®] was more evident in naïve patients, whom at year 4 achieved HSDS values of Δ+1.49 and Δ+1.47 (patients with GHD and SGA, respectively) (Figure 1).
- Omnitrope[®] had a greater impact on mean peak-centred HVSDS in naïve patients with GHD (Δ +4.6) and SGA (Δ +3.6) (Figure 2).

SGA patients following 4 years treatment with Omnitrope®									
Lime (Months)									
10 7	Baseline	6	12	18	24	30	36	42	48
8 -		Ţ	T_	т					
6 -				T _T	 _	T _T	T _T	_	
QS + -	_							ΙŢ	T _T
HVSDS (PC) (mean ± SD)	Ţ								
SDS (P	ТТ		- T						
₽ -2 - -4 -									
_6 _	l] n	n	n	n	n	n	n	n	n
GHD naïve 🔶	707	1507	1408	1256	1118	917	783	606	482
SGA naïve 📕	254	570	563	552	530	467	413	336	260
GHD pre-treated 🔺	260	334	306	272	243	199	166	123	83
SGA pre-treated ●	134	162	148	126	111	97	77	60	50

Conclusions

- Across all the indications examined, the data on evaluable patients to date show no evidence for an increased risk of developing unexpected AEs or new malignancies during Omnitrope® treatment.
- The results of this 4-year analysis demonstrate that Omnitrope®

treatment remains efficacious and well tolerated in the majority of rhGH-treated children.

• The ongoing PATRO Children study will continue to provide valuable safety and efficacy data for long-term treatment with Omnitrope[®].

References

- Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010; 95: 167–177.
- European Medicines Agency 2008. Omnitrope[®] European Public Assessment Report 2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_ for_the_public/human/000607/WC500043689.pdf
- Pfäffle R, Schwab KO, Marginean O, et al. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope[®] in children requiring growth hormone treatment. Ther Adv Endocrinol Metab 2013; 4: 3–11.

Acknowledgements and disclosures

R.Pfäffle, S.Kanumakala, C.Höybye, B.Kriström, T.Battelino and M.Colle have acted as advisors and/or speakers for Sandoz GmbH. Markus Zabransky is an employee of Sandoz GmbH.

This study was funded by Sandoz GmbH.

Medical writing support was provided by Fiona Goodwin and Tony Reardon, Spirit Medical Communications Ltd., supported by Sandoz GmbH.

